Vitamin C in improving skin brightness and enhancing overall skin parameters

A single arm clinical study to evaluate the efficacy of the Vitamin C in improving skin brightness and enhancing overall skin parameters - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/09/095336

Enrollment

Registered

2025-09-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Neutriderm Vitamin C Serum: Dose: Gently use approx. 5-6 drops of the Vitamin C serum on the face twice a day for 4 weeks. Route of Administration: Topical Control Interve

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gender: Male or Female with age 18-45 2) Subjects with mild pigmented skin. 3) Subjects willing to give written informed consent 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 3. Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 4. Have participated in any interventional clinical trial in the previous 90 days. 5. Have a known sensitivity to any of the constituents of the test product 6. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. 7. Have not skin related issues

Design outcomes

Primary

Measure	Time frame
1. change in Skin Gloss 2. change in Skin Pigmentation 3. change in Skin Hydration 4. change in Dark Spots 5. change in TEWL 6. Change in Dermat evaluation 7. visioscan 8. DSLR imagingTimepoint: At time T0, day 14 and day 28	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results